Cargando…

Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs

In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Jehun, Kang, Seongmin, Choi, Seung Won, Seo, Kwang Won, Lee, Sunggun, So, Min Wook, Lim, Doo-Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Cases with a Message
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167494/ https://www.ncbi.nlm.nih.gov/pubmed/32314010 http://dx.doi.org/10.1007/s00296-020-04584-7

Ejemplares similares

Effects of Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Response to Periodontal Treatment in Patients with Rheumatoid Arthritis
por: Jung, Gyu-Un, et al.
Publicado: (2018)

Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs
por: Ideguchi, Haruko, et al.
Publicado: (2006)

Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Costello, Ruth E, et al.
Publicado: (2020)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
por: Wang, Susan Siyu, et al.
Publicado: (2023)

Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis
por: Guski, Louise S., et al.
Publicado: (2023)

Changing Patterns of Medical Visits and Factors Associated with No-show in Patients with Rheumatoid Arthritis during COVID-19 Pandemic
por: Kim, Yena, et al.
Publicado: (2020)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
por: Kerola, Anne Mirjam, et al.
Publicado: (2021)

Cost-effectiveness of Anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China
por: Tian, Feng, et al.
Publicado: (2021)

The variety of clinical presentations in IgG4-related disease in Rheumatology
por: Sebastian, Agata, et al.
Publicado: (2017)

Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs
por: Mori, Shunsuke
Publicado: (2011)

Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
por: Jin, Xue-Mei, et al.
Publicado: (2014)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
por: Xia, Yunfei, et al.
Publicado: (2016)

Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies
por: Fazeli, Mir Sohail, et al.
Publicado: (2021)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Post-COVID-19 exacerbation of fibrodysplasia ossificans progressiva with multiple flare-ups and extensive heterotopic ossification in a 45-year-old female patient
por: Grgurevic, Lovorka, et al.
Publicado: (2021)

Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis
por: Plein, Sven, et al.
Publicado: (2020)

Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study
por: Deng, Daihua, et al.
Publicado: (2020)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2023)

Erratum: Correction of Author’s Affiliation in the Article “Changing Patterns of Medical Visits and Factors Associated With No-show in Patients With Rheumatoid Arthritis During COVID-19 Pandemic”
por: Kim, Yena, et al.
Publicado: (2023)

Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review
por: González-Moreno, Juan, et al.
Publicado: (2018)

Evaluating various radiographic methods of shoulder joint damage in patients with rheumatoid arthritis receiving biological disease-modifying antirheumatic drugs
por: Sugimori, Kazuhito, et al.
Publicado: (2020)

Assessment of anti-CarP antibodies, disease activity and quality of life in rheumatoid arthritis patients on conventional and biological disease-modifying antirheumatic drugs
por: Kumar, Sudhir, et al.
Publicado: (2017)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
por: van Vollenhoven, Ronald, et al.
Publicado: (2018)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
por: Joo, Young Bin, et al.
Publicado: (2022)

Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
por: Choy, Ernest, et al.
Publicado: (2019)

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
por: Sato, Shuzo, et al.
Publicado: (2021)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
por: Judge, Andy, et al.
Publicado: (2017)

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis
por: Nguyen, Thao H. P., et al.
Publicado: (2022)

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
por: Schiff, Michael, et al.
Publicado: (2017)

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
por: Ozen, Gulsen, et al.
Publicado: (2019)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

The effect of disease-modifying antirheumatic drugs on sleep and quality of life in older patients with rheumatoid arthritis
por: Azizli, Ali, et al.
Publicado: (2023)

Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010
por: Ichinose, Kunihiro, et al.
Publicado: (2018)

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs
por: Sokka, Tuulikki, et al.
Publicado: (2008)

Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2020)

Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis
por: Deyab, Gia, et al.
Publicado: (2021)

Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Hernández-Cruz, Blanca, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n540t1s0bcjqd25taem6la86oh